Compare ClearPoint Neuro Inc (CLPT) vs Icl Group Ltd (ICL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs Icl Group Ltd — how do they compare? ClearPoint Neuro Inc trades at $14.77 (market cap $454.21M), while Icl Group Ltd trades at $5.45 (market cap $6.94B). The key difference: Icl Group Ltd is far larger — about 15.3× ClearPoint Neuro Inc's market cap, and Icl Group Ltd pays a 3.86% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CLPT | ICL | |
|---|---|---|
Market Cap | $454.21M | $6.94B |
Sector | Health | Basic Materials |
52-Week High | $29.60 | $6.84 |
52-Week Low | $8.66 | $4.80 |
Enterprise Value | $488.79M | $9.58B |
Dividend Yield | — | 3.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $14.56, down slightly by 0.07% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 revenue growth to $42 million but missed earnings estimates with a loss of $0.38 per share, reflecting ongoing investment in clinical and preclinical services. Despite negative net income margins and cash flow challenges, analyst consensus remains unanimously bullish with 3 buy ratings.
The outlook hinges on successful execution of growth initiatives in neuro drug delivery and regulatory progress with partners, though high valuation multiples and persistent losses pose significant risks. Near-term catalysts include Q3 2026 earnings and partner developments, but investors face volatility from operational cash burn and competitive pressures.
ICL trades at $5.34, up 0.56% today, with a bullish technical signal supported by moving averages. Recent Q2 2026 earnings beat expectations with EPS of $0.12 versus $0.11 expected, continuing a trend of positive surprises. The company maintains stable cash flow from operations around $1.1B annually and pays consistent dividends, with recent payments of $0.05 and $0.06 per share.
Outlook remains cautious with 100% analyst hold ratings citing fair valuation. Risks include declining profit margins (3.95% net margin in 2025) and exposure to commodity price volatility. The stock offers moderate value with P/E of 22.25 and P/S of 0.89, but requires monitoring of cost transformation program effectiveness amid raw material inflation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →
